153 related articles for article (PubMed ID: 23467750)
1. Sequence mutations of the substrate binding pocket of stem cell factor and multidrug resistance protein ABCG2 in renal cell cancer: a possible link to treatment resistance.
Zoernig I; Ziegelmeier C; Lahrmann B; Grabe N; Jäger D; Halama N
Oncol Rep; 2013 May; 29(5):1697-700. PubMed ID: 23467750
[TBL] [Abstract][Full Text] [Related]
2. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma.
Mizuno T; Terada T; Kamba T; Fukudo M; Katsura T; Nakamura E; Ogawa O; Inui K
Ann Oncol; 2010 Jun; 21(6):1382-1383. PubMed ID: 20348146
[No Abstract] [Full Text] [Related]
3. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Mizuno T; Fukudo M; Terada T; Kamba T; Nakamura E; Ogawa O; Inui K; Katsura T
Drug Metab Pharmacokinet; 2012; 27(6):631-9. PubMed ID: 22673043
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
5. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
6. Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction.
Low SK; Fukunaga K; Takahashi A; Matsuda K; Hongo F; Nakanishi H; Kitamura H; Inoue T; Kato Y; Tomita Y; Fukasawa S; Tanaka T; Nishimura K; Uemura H; Hara I; Fujisawa M; Matsuyama H; Hashine K; Tatsugami K; Enokida H; Kubo M; Miki T; Mushiroda T
PLoS One; 2016; 11(2):e0148177. PubMed ID: 26914831
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
8. SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes.
Jeong HW; Cui W; Yang Y; Lu J; He J; Li A; Song D; Guo Y; Liu BH; Chai L
PLoS One; 2011 Apr; 6(4):e18372. PubMed ID: 21526180
[TBL] [Abstract][Full Text] [Related]
9. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2.
Henriksen U; Fog JU; Litman T; Gether U
J Biol Chem; 2005 Nov; 280(44):36926-34. PubMed ID: 16107343
[TBL] [Abstract][Full Text] [Related]
10. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer.
Zhu MM; Tong JL; Xu Q; Nie F; Xu XT; Xiao SD; Ran ZH
PLoS One; 2012; 7(8):e41763. PubMed ID: 22870247
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
Han B; Zhang JT
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
14. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
[TBL] [Abstract][Full Text] [Related]
15. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
16. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.
Ozvegy C; Váradi A; Sarkadi B
J Biol Chem; 2002 Dec; 277(50):47980-90. PubMed ID: 12374800
[TBL] [Abstract][Full Text] [Related]
17. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Shukla S; Robey RW; Bates SE; Ambudkar SV
Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
[TBL] [Abstract][Full Text] [Related]
19. ABCG2: determining its relevance in clinical drug resistance.
Robey RW; Polgar O; Deeken J; To KW; Bates SE
Cancer Metastasis Rev; 2007 Mar; 26(1):39-57. PubMed ID: 17323127
[TBL] [Abstract][Full Text] [Related]
20. Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport.
Hou YX; Li CZ; Palaniyandi K; Magtibay PM; Homolya L; Sarkadi B; Chang XB
Biochemistry; 2009 Sep; 48(38):9122-31. PubMed ID: 19691360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
